Table 5.
Multivariate analysis for patients characteristics, treatments and mutations in FLT3 wt and NPM1 wt patients.
| Patients Characteristics | CR | OS | DFS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| HSCT | - | - | 0.42 (0.16–1.09) | 0.0744 | 0.24 (0.09–0.62) | 0.0032 |
| Age > 60 | - | - | 1.02 (0.43–2.41) | 0.9624 | 1.12 (0.51–2.45) | 0.7778 |
| Sex male | 2.57 (0.66–11.53) | 0.1846 | 0.77 (0.33–1.78) | 0.5462 | - | - |
| De novo | 0.65 (0.11–2.96) | 0.5985 | 0.88 (0.36–2.16) | 0.7753 | 1.29 (0.50–3.33) | 0.5997 |
| ECOG PS 2–3 | - | - | 2.24 (0.54–9.31) | 0.2681 | - | - |
| DNMT3A | - | - | 2.58 (0.80–8.28) | 0.1105 | 3.57 (1.07–11.89) | 0.0383 |
| TET2 | 0.15 (0.02–0.94) | 0.0387 | 2.32 (0.70–7.63) | 0.1670 | 1.93 (0.62–6.03) | 0.2600 |
| RUNX1 | 0.44 (0.1–1.99) | 0.2747 | 2.20 (0.93–5.24) | 0.0741 | 1.93 (0.83–4.50) | 0.1277 |
| CEBPA2 * | 3.93 (0.47–98.06) | 0.2806 | 0.20 (0.04–0.92) | 0.0387 | 0.13 (0.03–0.58) | 0.0070 |
| ASXL1 | 1.38 (0.24–11.14) | 0.7367 | - | - | - | - |
| NRAS | - | - | 1.21 (0.38–3.87) | 0.7457 | 1.05 (0.34–3.29) | 0.9284 |
| SRSF2 | 0.08 (0.01–0.5) | 0.0093 | - | - | - | - |
| U2AF1 | - | - | 3.39 (1.16–9.92) | 0.0260 | 3.81 (1.35–10.78) | 0.0117 |
* CEBPA2 indicates the presence of a double mutation.